GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List

Range Low Price High Price Comment
30 days $4.45 $5.86 Thursday, 18th Apr 2024 BCRX stock ended at $4.50. This is 1.75% less than the trading day before Wednesday, 17th Apr 2024. During the day the stock fluctuated 4.90% from a day low at $4.49 to a day high of $4.71.
90 days $4.45 $6.35
52 weeks $4.45 $9.07

Historical BioCryst Pharmaceuticals prices

Date Open High Low Close Volume
2023-12-29 $6.09 $6.10 $5.99 $5.99 2 077 925
2023-12-28 $6.18 $6.27 $6.03 $6.09 2 315 692
2023-12-27 $6.08 $6.19 $5.96 $6.19 2 858 545
2023-12-26 $6.02 $6.17 $5.94 $6.08 2 835 989
2023-12-22 $5.82 $6.07 $5.78 $5.94 2 464 130
2023-12-21 $5.73 $5.85 $5.67 $5.76 1 859 043
2023-12-20 $5.97 $5.97 $5.61 $5.64 3 175 066
2023-12-19 $6.11 $6.27 $5.99 $6.05 2 802 074
2023-12-18 $6.16 $6.26 $6.04 $6.07 2 340 921
2023-12-15 $6.47 $6.48 $6.05 $6.19 9 985 188
2023-12-14 $6.43 $6.58 $6.32 $6.43 6 215 779
2023-12-13 $5.93 $6.30 $5.72 $6.30 6 822 273
2023-12-12 $5.38 $6.09 $5.30 $5.95 7 449 885
2023-12-11 $5.85 $5.85 $5.25 $5.39 6 885 375
2023-12-08 $5.65 $5.82 $5.60 $5.69 5 120 120
2023-12-07 $5.54 $6.00 $5.42 $5.67 9 851 865
2023-12-06 $5.50 $5.71 $4.98 $5.51 16 179 093
2023-12-05 $6.12 $6.38 $6.04 $6.13 3 217 134
2023-12-04 $6.20 $6.35 $6.03 $6.19 2 559 332
2023-12-01 $5.93 $6.17 $5.73 $6.15 4 370 494
2023-11-30 $5.52 $5.92 $5.50 $5.88 3 224 656
2023-11-29 $5.49 $5.65 $5.37 $5.43 2 494 875
2023-11-28 $5.29 $5.39 $5.15 $5.39 2 161 647
2023-11-27 $5.48 $5.50 $5.26 $5.32 2 411 261
2023-11-24 $5.36 $5.64 $5.33 $5.52 1 232 424
Click to get the best stock tips daily for free!

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II... BCRX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT